Tang Capital Management
Latest statistics and disclosures from Tang Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TARS, EOLS, KALV, ANAB, MIRM, and represent 25.90% of Tang Capital Management's stock portfolio.
- Added to shares of these 10 stocks: INBX (+$25M), Outlook Therapeutics (+$19M), IMNM (+$18M), APLT (+$15M), EOLS (+$15M), MOR (+$15M), ACET (+$13M), Lenz Therapeutics (+$12M), RCKT (+$11M), ANIP (+$10M).
- Started 25 new stock positions in NVDA, DERM, KURA, IMNM, MOR, LQDA, ANIP, ATRA, Lenz Therapeutics, APLT.
- Reduced shares in these 10 stocks: Mirati Therapeutics (-$92M), , LIANY (-$42M), AXSM (-$26M), Gracell Biotechnologies (-$22M), RVMD (-$20M), ANAB (-$14M), Theseus Pharmaceuticals (-$13M), BEAM (-$9.5M), ASND (-$8.8M).
- Sold out of its positions in ADMA, TLPH, ACRS, ARE, ASND, AXSM, BOH, BEAM, BIO, BPMC.
- Tang Capital Management was a net seller of stock by $-238M.
- Tang Capital Management has $960M in assets under management (AUM), dropping by -11.25%.
- Central Index Key (CIK): 0001232621
Tip: Access up to 7 years of quarterly data
Positions held by Tang Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tang Capital Management
Tang Capital Management holds 99 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals (TARS) | 8.5 | $82M | +2% | 2.3M | 36.35 |
|
| Evolus (EOLS) | 6.0 | $58M | +33% | 4.1M | 14.00 |
|
| Kalvista Pharmaceuticals (KALV) | 5.1 | $49M | +19% | 4.1M | 11.86 |
|
| Anaptysbio Inc Common (ANAB) | 3.1 | $30M | -31% | 1.3M | 22.52 |
|
| Mirum Pharmaceuticals (MIRM) | 3.1 | $30M | +4% | 1.2M | 25.12 |
|
| Altimmune Com New (ALT) | 2.9 | $28M | 2.8M | 10.18 |
|
|
| Immunocore Hldgs Ads (IMCR) | 2.7 | $26M | 406k | 65.00 |
|
|
| Inhibrx (INBX) | 2.5 | $25M | NEW | 700k | 34.96 |
|
| Eli Lilly & Co. (LLY) | 2.2 | $21M | -10% | 27k | 777.96 |
|
| Vaxcyte (PCVX) | 2.1 | $21M | 300k | 68.31 |
|
|
| Ptc Therapeutics I (PTCT) | 2.1 | $20M | -22% | 700k | 29.09 |
|
| Outlook Therapeutics | 2.0 | $19M | NEW | 1.6M | 11.94 |
|
| Rocket Pharmaceuticals (RCKT) | 1.9 | $18M | +164% | 660k | 26.94 |
|
| Immunome (IMNM) | 1.9 | $18M | NEW | 720k | 24.68 |
|
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 1.8 | $18M | -2% | 1.0M | 16.89 |
|
| Ventyx Biosciences (VTYX) | 1.8 | $17M | +55% | 3.1M | 5.50 |
|
| Atea Pharmaceuticals (AVIR) | 1.7 | $17M | 4.1M | 4.04 |
|
|
| Elevation Oncology (ELEV) | 1.6 | $16M | -16% | 3.1M | 5.13 |
|
| Applied Therapeutics (APLT) | 1.6 | $15M | NEW | 2.2M | 6.80 |
|
| Adicet Bio (ACET) | 1.6 | $15M | +631% | 6.4M | 2.35 |
|
| Morphosys Sponsored Ads (MOR) | 1.5 | $15M | NEW | 801k | 18.14 |
|
| Cytomx Therapeutics (CTMX) | 1.5 | $14M | 6.5M | 2.18 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 1.3 | $13M | 3.6M | 3.64 |
|
|
| GSK Sponsored Adr (GSK) | 1.3 | $13M | 300k | 42.87 |
|
|
| Lenz Therapeutics | 1.3 | $12M | NEW | 548k | 22.33 |
|
| Miragen Therapeutics (VRDN) | 1.3 | $12M | 693k | 17.51 |
|
|
| Zymeworks Del (ZYME) | 1.2 | $12M | 1.1M | 10.52 |
|
|
| Cargo Therapeutics (CRGX) | 1.1 | $10M | +190% | 467k | 22.32 |
|
| Intra Cellular Therapies (ITCI) | 1.1 | $10M | -31% | 150k | 69.20 |
|
| Biosante Pharmaceuticals (ANIP) | 1.1 | $10M | NEW | 150k | 69.13 |
|
| Aurinia Pharmaceuticals (AUPH) | 1.1 | $10M | +272% | 2.1M | 5.01 |
|
| Astrazeneca Sponsored Adr (AZN) | 1.1 | $10M | -11% | 150k | 67.75 |
|
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 1.0 | $9.9M | -16% | 500k | 19.73 |
|
| Cullinan Oncology (CGEM) | 1.0 | $9.7M | -25% | 571k | 17.04 |
|
| ACADIA Pharmaceuticals (ACAD) | 1.0 | $9.6M | +353% | 519k | 18.49 |
|
| Harmony Biosciences Hldgs In (HRMY) | 1.0 | $9.4M | +3% | 281k | 33.58 |
|
| Deciphera Pharmaceuticals (DCPH) | 1.0 | $9.4M | NEW | 600k | 15.73 |
|
| NVIDIA Corporation (NVDA) | 0.9 | $9.0M | NEW | 10k | 903.56 |
|
| Viking Therapeutics (VKTX) | 0.9 | $8.2M | NEW | 100k | 82.00 |
|
| Black Diamond Therapeutics (BDTX) | 0.8 | $8.1M | -11% | 1.6M | 5.07 |
|
| Precision Biosciences Com New | 0.8 | $8.0M | NEW | 590k | 13.56 |
|
| Dianthus Therapeutics (DNTH) | 0.8 | $7.9M | -47% | 265k | 30.00 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 0.8 | $7.9M | -45% | 117k | 68.16 |
|
| Biohaven (BHVN) | 0.8 | $7.7M | 140k | 54.69 |
|
|
| Arvinas Ord (ARVN) | 0.8 | $7.4M | +125% | 180k | 41.28 |
|
| Iovance Biotherapeutics (IOVA) | 0.8 | $7.4M | -50% | 500k | 14.82 |
|
| Vanda Pharmaceuticals (VNDA) | 0.7 | $7.2M | +605% | 1.8M | 4.11 |
|
| Cytokinetics Com New (CYTK) | 0.7 | $7.0M | -9% | 100k | 70.11 |
|
| Apogee Therapeutics (APGE) | 0.7 | $6.6M | NEW | 100k | 66.45 |
|
| Ionis Pharmaceuticals (IONS) | 0.7 | $6.5M | -25% | 150k | 43.35 |
|
| Verastem Com New (VSTM) | 0.7 | $6.4M | -26% | 542k | 11.80 |
|
| Design Therapeutics (DSGN) | 0.6 | $6.0M | 1.5M | 4.03 |
|
|
| Nkarta (NKTX) | 0.6 | $5.9M | 550k | 10.81 |
|
|
| Beigene Sponsored Adr (BGNE) | 0.6 | $5.8M | -56% | 37k | 156.39 |
|
| Intellia Therapeutics (NTLA) | 0.6 | $5.5M | 200k | 27.51 |
|
|
| Enanta Pharmaceuticals (ENTA) | 0.5 | $5.2M | 300k | 17.46 |
|
|
| Fate Therapeutics (FATE) | 0.5 | $5.1M | 700k | 7.34 |
|
|
| Heron Therapeutics (HRTX) | 0.5 | $5.1M | 1.9M | 2.77 |
|
|
| Bioatla (BCAB) | 0.5 | $5.1M | -41% | 1.5M | 3.44 |
|
| Reneo Pharmaceuticals (RPHM) | 0.5 | $5.0M | -10% | 3.0M | 1.66 |
|
| Meta Platforms Cl A (META) | 0.5 | $4.9M | NEW | 10k | 485.58 |
|
| Bolt Biotherapeutics (BOLT) | 0.5 | $4.8M | -6% | 3.4M | 1.40 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.4 | $4.3M | NEW | 100k | 42.86 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.4 | $4.1M | 800k | 5.08 |
|
|
| Century Therapeutics (IPSC) | 0.4 | $3.8M | -15% | 900k | 4.18 |
|
| Bluebird Bio (BLUE) | 0.3 | $3.2M | +47% | 2.5M | 1.28 |
|
| Cortexyme (QNCX) | 0.3 | $3.1M | -8% | 2.9M | 1.06 |
|
| Equity Comwlth Com Sh Ben Int (EQC) | 0.3 | $3.1M | -44% | 165k | 18.88 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.3 | $3.1M | NEW | 50k | 62.24 |
|
| Genmab A/s Sponsored Ads (GMAB) | 0.3 | $3.0M | NEW | 100k | 29.91 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.3 | $2.8M | NEW | 300k | 9.40 |
|
| Kinnate Biopharma (KNTE) | 0.3 | $2.6M | -62% | 978k | 2.66 |
|
| Athira Pharma (ATHA) | 0.2 | $2.3M | -26% | 853k | 2.74 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.2 | $2.3M | -67% | 1.4M | 1.58 |
|
| Amarin Corp Spons Adr New (AMRN) | 0.2 | $2.2M | -19% | 2.5M | 0.89 |
|
| Liquidia Corporation Com New (LQDA) | 0.2 | $2.2M | NEW | 150k | 14.75 |
|
| Kura Oncology (KURA) | 0.2 | $2.1M | NEW | 100k | 21.33 |
|
| Passage Bio (PASG) | 0.2 | $2.0M | -37% | 1.5M | 1.35 |
|
| New York Community Ban (NYCB) | 0.2 | $2.0M | -62% | 607k | 3.22 |
|
| Aligos Therapeutics (ALGS) | 0.2 | $1.6M | -24% | 1.7M | 0.98 |
|
| Enzo Biochem (ENZ) | 0.2 | $1.6M | -25% | 1.3M | 1.27 |
|
| Tg Therapeutics (TGTX) | 0.2 | $1.5M | 100k | 15.21 |
|
|
| Atara Biotherapeutics (ATRA) | 0.1 | $1.3M | NEW | 1.9M | 0.69 |
|
| Seer Com Cl A (SEER) | 0.1 | $1.3M | NEW | 674k | 1.90 |
|
| Inflarx Nv (IFRX) | 0.1 | $1.2M | -58% | 769k | 1.54 |
|
| Avrobio Ord (AVRO) | 0.1 | $1.1M | NEW | 853k | 1.28 |
|
| Acumen Pharmaceuticals (ABOS) | 0.1 | $1000k | 247k | 4.05 |
|
|
| Revance Therapeutics (RVNC) | 0.1 | $984k | NEW | 200k | 4.92 |
|
| Atyr Pharma Com New (LIFE) | 0.1 | $919k | 471k | 1.95 |
|
|
| Seres Therapeutics (MCRB) | 0.1 | $702k | -49% | 907k | 0.77 |
|
| Uniqure Nv SHS (QURE) | 0.1 | $696k | -77% | 134k | 5.20 |
|
| Eagle Pharmaceuticals (EGRX) | 0.1 | $623k | 119k | 5.24 |
|
|
| Kezar Life Sciences (KZR) | 0.1 | $621k | +124% | 689k | 0.90 |
|
| Journey Med Corp (DERM) | 0.1 | $510k | NEW | 139k | 3.68 |
|
| Molecular Partners Ads (MOLN) | 0.0 | $420k | 100k | 4.20 |
|
|
| Nextcure (NXTC) | 0.0 | $322k | -69% | 145k | 2.23 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.0 | $284k | -50% | 100k | 2.84 |
|
| Erasca (ERAS) | 0.0 | $206k | -33% | 100k | 2.06 |
|
| Relmada Therapeutics (RLMD) | 0.0 | $1.8k | NEW | 382.00 | 4.65 |
|
Past Filings by Tang Capital Management
SEC 13F filings are viewable for Tang Capital Management going back to 2011
- Tang Capital Management 2024 Q1 filed May 15, 2024
- Tang Capital Management 2023 Q4 filed Feb. 14, 2024
- Tang Capital Management 2023 Q3 filed Nov. 14, 2023
- Tang Capital Management 2023 Q2 filed Aug. 14, 2023
- Tang Capital Management 2023 Q1 filed May 15, 2023
- Tang Capital Management 2022 Q4 filed Feb. 14, 2023
- Tang Capital Management 2022 Q3 filed Nov. 14, 2022
- Tang Capital Management 2022 Q2 filed Aug. 15, 2022
- Tang Capital Management 2022 Q1 filed May 16, 2022
- Tang Capital Management 2021 Q4 filed Feb. 14, 2022
- Tang Capital Management 2021 Q3 filed Nov. 15, 2021
- Tang Capital Management 2021 Q2 filed Aug. 16, 2021
- Tang Capital Management 2021 Q1 filed May 17, 2021
- Tang Capital Management 2020 Q4 filed Feb. 16, 2021
- Tang Capital Management 2020 Q3 filed Nov. 16, 2020
- Tang Capital Management 2020 Q2 filed Aug. 14, 2020